Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 50,439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Clear all

Conditions: Prostate Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix; Procedure · Drug · Other + 1 more
Lead sponsor: Sean Sachdev; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Tobacco Dependence
Interventions: C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening; Behavioral · Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Prostate Cancer
Interventions: MR-Guided Prostate SBRT; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Bone Cyst
Interventions: Curettage with puncture (C & P), Curette, Vitoss morsels; Procedure · Device
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 2 Years to 21 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Loma Linda, California • Wilmington, Delaware + 7 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Timeline: 2023 – 2043
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer, Pancreatic Islet Cell Tumors, Lymph Node Mass, Lymphadenopathy, GIST
Interventions: Endoscopic ultrasound fine needle aspiration; Device
Lead sponsor: Mauna Kea Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Atlanta, Georgia • Manhasset, New York • New York, New York + 1 more

Conditions: Myeloma
Interventions: Telephone Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 78 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: Poly ICLC, leukapheresis; Drug · Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diffuse Large B-cell Lymphoma
Interventions: GCS-100, Etoposide; Dexamethasone; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
Interventions: Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, Single Photon Emission Computed Tomography; Radiation · Drug · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Cancer Metastatic
Interventions: Nelitolimod; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
Interventions: Cerdulatinib, Rituximab; Drug · Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 23
States / cities: Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more

Conditions: Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions: CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glioblastoma Multiforme of Brain
Interventions: CHM-1101 CAR-T cells; Biological
Lead sponsor: Chimeric Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Duarte, California • Austin, Texas

Conditions: Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Interventions: Larotrectinib monotherapy, 131I therapy; Drug · Radiation
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 6
States / cities: San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 3 more

Conditions: Carcinoma, Non-small-cell Lung
Interventions: erlotinib and bexarotene; Drug
Lead sponsor: Konstantin Dragnev; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 2
States / cities: Lebanon, New Hampshire • New York, New York

Conditions: Non Small Cell Lung Cancer
Interventions: LN-145, Durvalumab; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Odronextamab; Biological
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumor
Interventions: SKB264, Pembrolizumab; Drug
Lead sponsor: Klus Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Anderson, Indiana • Louisville, Kentucky • Annapolis, Maryland + 5 more

Conditions: Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
Interventions: Selinexor, Clarithromycin, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 74 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Cancer, Breast, Cancer-related Problem/Condition, Quality of Life, Hormone Dependent Neoplasms, Adherence, Medication
Interventions: "My Guide" (psychoeducation & self-management program); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Solid Tumor
Interventions: 23ME-01473; Drug
Lead sponsor: 23andMe, Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Portland, Oregon • San Antonio, Texas

Conditions: Differentiated Thyroid Cancer
Interventions: Cabozantinib, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 16 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 31
States / cities: Newport Beach, California • Sacramento, California • San Francisco, California + 27 more

Search by objective public record fields.

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

C-Raven, a Virtual Tobacco Cessation Intervention in the Community

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

Simple Bone Cysts in Kids

Study of Healthy Cohort for Early Detection of Cancer

Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract

Long-Term Follow Up Study for AMD3100 Patients

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

A Research Study for Latina Women With Breast Cancer

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy